Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
300%(3 trials)
Terminated
2(67%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

JBT-101 in Systemic Lupus Erythematosus (SLE)

NCT03093402
terminatedphase_2

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

NCT02466243
terminatedphase_2

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

NCT02465437

Clinical Trials (3)

Showing 3 of 3 trials
NCT03093402Phase 2

JBT-101 in Systemic Lupus Erythematosus (SLE)

Completed
NCT02466243Phase 2

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Terminated
NCT02465437Phase 2

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3